Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ ICU admission 81% Improvement Relative Risk Recovery time 49% Discharge 44% Time to discharge 43% c19early.org/j Farnoosh et al. Melatonin for COVID-19 RCT LATE TREATMENT Is late treatment with melatonin beneficial for COVID-19? Double-blind RCT 44 patients in Iran Faster recovery with melatonin (p=0.004) Farnoosh et al., Archives of Medical Research, doi:10.1016/j.arcmed.2021.06.006 Favors melatonin Favors control
Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial
Farnoosh et al., Archives of Medical Research, doi:10.1016/j.arcmed.2021.06.006
Farnoosh et al., Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A.., Archives of Medical Research, doi:10.1016/j.arcmed.2021.06.006
Jun 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 44 hospitalized patients in Iran, 24 treated with melatonin, showing faster recovery with treatment. There was no mortality.
risk of ICU admission, 81.5% lower, RR 0.19, p = 0.20, treatment 0 of 24 (0.0%), control 2 of 20 (10.0%), NNT 10.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
recovery time, 49.0% lower, relative time 0.51, p = 0.004, treatment 24, control 20.
risk of no hospital discharge, 44.4% lower, RR 0.56, p = 0.65, treatment 2 of 24 (8.3%), control 3 of 20 (15.0%), NNT 15.
time to discharge, 42.9% lower, relative time 0.57, p = 0.02, treatment 24, control 20.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Farnoosh et al., 23 Jun 2021, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 12 authors, average treatment delay 7.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMelatoninAll
Abstract: ARTICLE IN PRESS JID: ARCMED [mNS;July 3, 2021;15:24] Archives of Medical Research xxx (xxxx) xxx Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial Gholamreza Farnoosh,a Mostafa Akbariqomi,b Taleb Badri,c Mahdi Bagheri,d Morteza Izadi,d Ali Saeedi-Boroujeni,e Ehsan Rezaie,f Hadi Esmaeili Gouvarchin Ghaleh,g Hossein Aghamollaei,h Mahdi Fasihi-ramandi,f Kazem Hassanpour,i and GholamHossein Alishirih,∗ a Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran Microbiology Research Center, Systems Biology and poisonings Institute, Baqiyatallah university of Medical Sciences, Tehran, Iran c Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran d Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran e Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran f Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran g Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran h Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran i Department of Pediatric, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran b Applied Received for publication February 27, 2021; accepted June 17, 2021 (ARCMED_2021_2680). Abstract Background. Melatonin has been known as an anti-inflammatory agent and immune modulator that may address progressive pathophysiology of coronavirus disease 2019 (COVID-19).Aim of the study. To evaluate the clinical efficacy of adjuvant, use of melatonin in patients with COVID-19. Methods. This single-center, double-blind, randomized clinical trial included 74 hospitalized patients with confirmed mild to moderate COVID-19 at Baqiyatallah Hospital in Tehran, Iran, from April 25, 2020–June 5, 2020. Patients were randomly assigned in a 1:1 ratio to receive standard of care and standard of care plus melatonin at a dose of 3 mg three times daily for 14 d. Clinical characteristics, laboratory, and radiological findings were assessed and compared between two study groups at baseline and post-intervention. Safety and clinical outcomes were followed up for four weeks. Results. A total of 24 patients in the intervention group and 20 patients in the control group completed the treatment. Compared with the control group, the clinical symptoms such as cough, dyspnea, and fatigue, as well as the level of CRP and the pulmonary involvement in the intervention group had significantly improved (p <0.05). The mean time of hospital discharge of patients and return to baseline health was significantly shorter in the intervention group compared to the control group (p <0.05). No deaths and adverse events were observed in both groups. Conclusions. Adjuvant use of melatonin has a potential to improve clinical symptoms of COVID-19 patients and contribute to a faster return of patients to baseline health. © 2021 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved. Keywords: COVID-19, Melatonin, Clinical trial, Adjunctive therapy. 0188-4409/$ - see front matter. Copyright © 2021 Instituto Mexicano del Seguro Social (IMSS). Published by..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit